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Background: Malignant gliomas represent the most common primary brain tumors. The prognosis of patients with
malignant gliomas is poor in spite of current intensive therapy and novel therapeutic modalities are needed. Here
we report that norcantharidin is effective in growth inhibition of glioma cell lines in vitro.
Methods: Glioma cell lines (U87 and C6) were treated with norcantharidin. The effects of norcantharidin on the
proliferation and apoptosis of glioma cells were measured by 3-[4,5-dimethylthiazol-2-thiazolyl]-2,5-diphenyl-tetrazolium
bromide (MTT) assay and flow cytometry. Western blotting was employed to determine the signaling pathway
changes.
Results: The results showed that norcantharidin effectively inhibited cell growth and induced apoptosis in glioma
cells, which was concurrent with inhibition of the expression of phospho-MEK and phospho-ERK. Furthermore, the
expression anti-apoptotic proteins Bcl-2 and Mcl-1 significantly reduced, but no changes in Bcl-xL and Bax.
Conclusions: Our findings demonstrate that norcantharidin is effective for growth inhibition of glioma cell lines
and suggest that norcantharidin may be a new therapeutic option for patients with glioma.
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Malignant gliomas are the most common primary tumors
of the central nervous system in adults. Surgical resec-
tion with adjuvant radiotherapy and temozolomide-based
chemotherapy are the mainstays of treatment [1]. Despite
tremendous efforts in diagnosis and therapeutic strategies,
the clinical outcome remains dismaying. Because of the
infiltrative growth of gliomas, it is difficult to resect the
whole tumor without causing serious damage of the brain.
Therefore, innovative treatment approaches are urgently
needed [2,3].
Recent publications indicate that the majority of gliomas
display upregulated Raf/MEK/extracellular signal-regulated
kinase (ERK) pathway, which is an essential serine/threo-
nine kinase constituent of the mitogen-activated protein
kinase (MAPK) pathway. Upon activation by growth factors,* Correspondence: zhengjie256@126.com
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unless otherwise stated.serum, cytokines, and osmotic stresses, ERK can phos-
phorylate and regulate multiple substrates such as cyto-
skeletal proteins, kinases, and transcription factors. These
events in turn result in gene expression changes and regulate
many fundamental cellular functions such as cell growth,
proliferation, and apoptosis. The upregulation of the Raf/
MEK/ERK pathway has been proven to take part in the
amplification of mitogenic stimuli and promotion of cellu-
lar proliferation of malignant gliomas [4-6]. Therefore
downregulation of the Raf/MEK/ERK pathway may repre-
sent appropriate alternate therapy for glioma patients [7].
Cantharidin (exo-2,3-dimethyl-7-oxabicyclo-, hep-tane-
2,3-dicarb-oxylic acidanhydride) is a bioactive compound,
purified from mylabris, the dried body of the Chinese blis-
ter beetle. Because of severe nephrotoxicity and inflamma-
tory side effects, CTD has been modified to a demethylated
form, norcantharidin (NCTD) [8]. Moreover, many studies
have reported that NCTD could exert its anti-tumor
characteristics on various cancer cells such as bladder
carcinoma, leukemia, colorectal carcinoma, hepatoma,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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reported to induce apoptosis in DAOY and UW228 me-
dulloblastoma cells through inhibition of Wnt/β-catenin
signaling activation [13]. However, the molecular mecha-
nisms are still not well understood.
In the present study, we attempt to investigate the growth
inhibition effect and the anti-cancer mechanism of NCTD
in the glioma cell lines U87 and C6. Our results suggested
that Bcl-2 family proteins participated in the apoptosis in-
duced by NCTD. In addition, it was revealed that NCTD
may exert its anti-cancer activity through the suppression
of the Raf/MEK/ERK pathway.
Methods
Cells and reagents
Glioma cell lines U87 and C6 were purchased from
American Type Culture Collection (Manassas, VA, USA).
All cell lines were maintained in Dulbecco’s Modified
Eagle Medium (DMEM) supplemented with 10% fetal bo-
vine serum (FBS) and P/S solution (10,000 U/mL penicil-
lin, 10,000 μg/mL sreptomycin) at 37°C and 5% CO2.
NCTD was purchased from Sigma Chemical (St Louis,
MO, USA) and dissolved in dimethyl sulfoxide (DMSO).
MTT viability assay
Cell viability was measured by 3-[4,5-dimethylthiazol-2-
thiazolyl]-2,5-diphenyl- tetrazolium bromide (MTT) assay.
Glioma cells were seeded in 96-well culture clusters
(Corning, NY, USA) at a density of 5,000 to 6,000 cells/well
in 100 μL medium and incubated at 37°C in a humidified
incubator for 24 h. On the following day, cells were
treated with desired concentrations of NCTD. Four hours
before desired time points, 10 μL of 10 mg/mL MTT was
added. After incubation for 4 h, the plates were depleted
and 200 μL DMSO was added to each well, and viable
cells detected by measuring absorbance at 570 nm using
MRX II absorbance reader (DYNEX Technologies,
Chantilly, VA, USA). The cell viability was expressed asFigure 1 Dose- and time-dependent inhibition of proliferation of glio
with various doses of NCTD for 24 h. (B) The cells were treated by 100 μM
survival rates were determined by MTT methods. Cell viability was expresse
were from three independent experiments. *P <0.05 compared to the contthe percentage of absorbance in cells with NCTD treat-
ment versus the control group. All experimental con-
centrations were replicated in triplicate. Results were
expressed as means ± SD values.Apoptosis analysis by flow cytometer
Apoptotic cells were measured with Annexin V/FITC kit
(BD Biosciences, Sparks, MD, USA) according to the
manufacturer’s instructions. Cells were cultured in six-
well plates at 3 × 105 cells per well and treated with the
agents for 10 h. The cells were harvested, washed with
cold PBS, and then resuspended in 500 μL of binding buf-
fer. A total of 5 μL of annexinV-FITC solution and 10 μL
PI (1 g/mL) were added to these cells. Cells were then
incubated in the dark for 30 min at room temperature
prior to analysis by flow cytometry. Using flow cytometer
(Beckman Coulter FC500, USA) to detect apoptosis
through channels two and three. In all, 10,000 cells
were collected for each sample.Western blotting analysis
Cells were plated in tissue culture dishes overnight and
treated with different concentrations of NCTD for 24 h.
After harvest and washout with new fresh culture medium,
the cells were resuspended in lysis buffer containing prote-
ase inhibitor cocktail (Amresco, Solon, OH, USA). Equal
amount of total protein extracts were separated by 10%
standard sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE) and transferred onto a polyvinyli-
dene fluoride (PVDF) membrane (0.45 mm, Millipore,
Bedford, MA, USA). Membranes were blocked with 5%
fat-free milk and 0.1% Tween-20 in Tris-buffered saline,
then incubated with the following primary antibodies as
follows: MEK, ERK, phospho-MEK, phospho-ERK, Bcl-2,
Bcl-xL, Mcl-1, Bax, and GAPDH (Cell Signaling Technol-
ogy). Horseradish peroxidase-linked anti-mouse or anti-
rabbit IgG were then used as secondary antibody, followedma cells by NCTD treatment. (A) U87 and C6 cell lines were treated
NCTD for various time periods. At the end of incubation, the cell
d as the percentage of cell survival compared with the control. Data
rol group.
Zheng et al. World Journal of Surgical Oncology 2014, 12:207 Page 3 of 6
http://www.wjso.com/content/12/1/207by detection by enhanced chemiluminescence (Amersham
Bioscience, Piscataway, NJ, USA).
Statistical analysis
Data were expressed as means ± standard deviation (SD).
Statistical analysis was done using one-way analysis of
variance (ANOVA) via SPSS 13.0 software (SPSS, Chicago,
IL, USA). A value of P <0.05 was considered statistically
significant.Figure 2 NCTD caused apoptotic death in U87 (A, C) and C6 (B, D) ce
with Annexin V/PI followed by FACS analysis. Representative FACS analysis
treatment showed four different cell populations marked as: double negati
positive and PI negative stained cells showing early apoptosis (lower right)
right), and finally PI positive and Annexin V negative stained cells showing
positive. *P <0.05 compared to the control group.Results
Cell growth inhibition of NCTD on glioma cells
In order to investigate the effect of NCTD on inhibition of
proliferation of glioma, we exposed U87 and C6 cells to
drug from 25 to 200 μM for desired time point. MTT as-
says demonstrated that NCTD exerted a dose- and time-
dependent cell growth inhibition of U87 and C6 cells. By
24 h, the average IC50s for NCTD of U87 and C6 cells
were 123.2 μM and 91.3 μM, respectively (Figure 1).lls. Following 10 h of cell treatments, cells were collected and stained
scatter-grams of Annexin V/PI stained 0, 10, 30, and 50 μM NCTD
ve (unstained) cells showing live cell population (lower left), Annexin V
, Annexin V/PI double-stained cells showing late apoptosis (upper
dead cells (upper left). Apoptosis was defined as Annexin V staining
Figure 3 NCTD inhibits Raf/MEK/ERK signaling pathway in U87 (A) and C6 (B) cells. Cells were treated with the indicated concentrations of
NCTD for 24 h. After treatment, whole cell protein extracts were prepared, and equal amounts of total protein were resolved on SDS-PAGE gels.
Western blotting analysis was performed using specific antibodies against the indicated proteins.
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In our assay, apoptotic death assay employing Annexin
V/PI staining followed by fluorescent activated cell sorter
(FACS) analysis clearly showed apoptotic effect of NCTD
on glioma cells. As shown in Figure 2, the four quadrants
in each panel correspond, respectively, to: necrotic cells
(upper left), apoptotic late cells (upper right), apoptotic
early cells (lower right), viable cells (lower left). Ten hours
after treatment with NCTD, the results confirmed a dose-
dependent apoptotic effect of NCTD on glioma cells.
NCTD inhibits Raf/MEK/ERK signaling pathway in glioma
cells
The Raf/MEK/ERK pathway is downstream of Ras activa-
tion, and tyrosine phosphorylation of these proteins is es-
sential for cancer cell proliferation. To correlate growth
inhibition and apoptotic induction with NCTD therapy,
we evaluated the effect of NCTD on the phosphorylation
of these proteins by western blotting. We compared the
phosphorylation of these proteins in cells treated withFigure 4 NCTD downregulates Bcl-2 and Mcl-1 levels in U87 (A) and C
cells were harvested after incubation with the indicated concentrations ofvarious concentrations of NCTD for 24 h. As shown in
Figure 3, the results of western blotting showed that
NCTD inhibited p-MEK and p-ERK dose-dependently
(Figure 3).
Effect of NCTD on the levels of pro-apoptotic protein Bax,
anti-apoptotic proteins Bcl-2, Bcl-xL, and Mcl-1
Because the intrinsic pathway of apoptosis is controlled
by Bcl-2 family proteins, and cell death decisions are
regulated by the balance between proapoptotic (for ex-
ample, Bax) and antiapoptotic (for example, Bcl-2, Bcl-xL,
Mcl-1, and so on) proteins. We also detected the effect of
agent treatment on such proteins. As shown in Figure 4,
NCTD–treated glioma cells for 24 h had little or no effect
on expression of Bcl-xL or Bax. However, treatment of
U87 and C6 cells with NCTD resulted in a significant
downregulation of Bcl-2 and Mcl-1. Together, this analysis
demonstrated NCTD-induced downregulation of Bcl-2
and Mcl-1 as reported previously but no change in Bcl-
xL and Bax.6 (B) cells, but has little effect on expression of Bcl-xL or Bax. The
NCTD for 24 h. GAPDH was used as an internal control.
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Malignant gliomas are the most prevalent primary brain
tumors in adults with relatively high rates of recurrences.
They display a poor response to conventional cytotoxic
chemotherapy. Thus, novel approaches to glioma therapy
are urgently needed.
The upregulation of the Raf/MEK/ERK cascade is one
of the principal Ras-regulated pathways, and has been
proven to be associated with glioma cell proliferation, sur-
vival, and migration. It has been suggested that downregu-
lation of the Raf/MEK/ERK pathway may be of great
promise as a target for preventing tumor cell growth [14].
Therefore, targeting Raf/MEK/ERK pathway is a promis-
ing strategy for glioma treatment. Our experiments indi-
cated that both U87 and C6 glioma cells were sensitive to
NCTD in vitro. NCTD inhibited the Raf/MEK/ERK path-
way through downregulation of p-MEK and p-ERK in a
concentration-dependent fashion, which is partially in
agreement of the previous studies [15]. As the Raf/MEK/
ERK pathway is one of the evolutionarily conserved MAPK
pathways that play critical roles in driving cell prolifera-
tion, survival, and preventing apoptosis, we tested effects
of NCTD on glioma cell proliferation and apoptosis. The
effect of NCTD on the inhibition of proliferation was
measured by MTT assay, and the results proved that
NCTD inhibited glioma cell growth in a time- and dose-
dependent manner in both U87 and C6 cells. To observe
the effect of NCTD on the induction of cell apoptosis, we
performed the apoptosis analysis by flow cytometer. Cell
apoptosis analysis showed that after treatment with
NCTD, both U87 and C6 cells revealed concentration-
dependent apoptosis.
One important target for chemotherapy is programmed
cell death, and the cell death was determined by the pro-
apoptotic and anti-apoptotic proteins. Bcl-2 family pro-
teins play a central role in the control of apoptosis [16].
Antiapoptotic members of Bcl-2 family, including Bcl-2,
Bcl-xL as well as Mcl-1 inhibit apoptosis by sequestering
Bax. Bax protein is a pro-apoptotic member and the in-
creased expression of this protein often associated with
the increased apoptosis in target cells [17]. Cancer cells
often express elevated levels of antiapoptotic members of
Bcl-2 family, so as to obtain survival and proliferation
advantage. Bcl-2 protein is the prototype of this family,
which targets intracellular organelles such as the endoplas-
mic reticulum, outer mitochondrial, and nuclear membranes
[18]. Mcl-1 act as an apical molecule in apoptosis control,
promoting cell survival by interfering at an early stage in a
cascade of events leading to release of cytochrome c from
mitochondria. It is reported that Mcl-1 is highly expressed
antiapoptotic protein in malignant tumors and cause
glioma cell resistance toward apoptosis induced by
chemotherapy or radiation therapy [19]. The molecular
mechanisms underlying the anticancer activity of NCTDhave been extensively studied. Previous studies linked the
anticancer activity of NCTD to downregulation of Bcl-2,
Bcl-xL and Mcl-1 since it was found that NCTD reduced
the level of these antiapoptotic Bcl-2 family proteins in
various cancer cells [11,20,21]. In our study, treatment of
U87 or C6 cells with NCTD resulted in a significant down-
regulation of Bcl-2 and Mcl-1. Nevertheless, there were
no significant changes in the expression of Bcl-xL or Bax
proteins after treatment U87 or C6 cells with NCTD for
24 h. These results suggested that NCTD induced apop-
tosis in glioma cell lines U87 or C6 through the downreg-
ulating of proapoptotic proteins Bcl-2 and Mcl-1.
Conclusion
In conclusion, we demonstrated that NCTD was an effect-
ive potential chemotherapeutic agent for the inhibition
proliferation and induction apoptosis of glioma cells. And
these results made NCTD a promising therapeutic agent
in the treatment of patients with glioma.
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